TickerFacts.

Company research / QDEL

QuidelOrtho Corp (QDEL)

Build a valuation ↗↓ Download CSV

CIK 0001906324 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Fiscal year ends around Jan 1

For the year ended 2025-12-28, QuidelOrtho Corp reported revenue of $2.73B. Revenue fell 1.9% from the prior annual period. Over the twelve months to 2026-06-28, revenue was $2.67B.

Key ratios (year ended 2025-12-28)

-33.7%
Operating margin
-41.5%
Net margin
-58.9%
Return on year-end equity
-1.9%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-28 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-28		2025-12-282024-12-292023-12-312023-01-01, Fiscal 20222022-01-02, Fiscal 20212021-01-03, Fiscal 2020
Revenue$2.67B$2.73B$2.78B$3.00B$3.27B$1.70B$1.66B
R&D Expense$180.90M$186.20M$218.70M$245.00M$187.90M$95.70M$84.30M
Operating Income-$824.70M-$919.20M-$1.96B$139.10M$843.70M$906.00M$1.06B
Depreciation & Amortization$454.20M$442.00M$453.40M$457.20M$283.60M$52.70M$48.80M
EBITDA-$370.50M-$477.20M-$1.51B$596.30M$1.13B$958.70M$1.11B
Net Income-$1.05B-$1.13B-$2.05B-$10.10M$548.70M$704.20M$810.30M
EPS (Diluted)n/a-$16.69-$30.54-$0.15$9.56$16.43$18.60
Total Assets$5.72B$5.77B$6.42B$8.56B$8.86B$2.43Bn/a
Total Liabilities$3.94B$3.85B$3.44B$3.56B$3.92B$501.00Mn/a
Long-Term Debtn/a$2.70B$2.49B$2.42B$2.65Bn/an/a
Shareholders' Equity$1.77B$1.92B$2.98B$5.01B$4.93B$1.93B$1.33B
Cash & Equivalents$123.40M$169.80M$98.30M$118.90M$292.90M$802.80Mn/a
Operating Cash Flow-$57.20M$105.20M$83.00M$280.20M$885.30M$805.90M$629.70M
Capital Expenditures$154.00M$188.20M$195.10M$209.30M$140.90M$292.80M$64.90M
Free Cash Flow-$211.20M-$83.00M-$112.10M$70.90M$744.40M$513.10M$564.80M
Share Repurchasesn/a$0$0$7.20M$74.30M$103.50M$43.70M
Shares Outstanding68.30M67.90M67.30M66.70M66.40M41.70Mn/a
Weighted Average Diluted Sharesn/a67.80M67.20M66.80M57.40M42.90M43.60M
EPS (Basic)n/a-$16.69-$30.54-$0.15$9.66$16.74$19.24

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView